Notice of Intent to Sole Source – Oncotype DX Cancer Testing Services
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Defense Health Agency Contracting Activity intends to award a firm-fixed-price sole-source contract to Genomic Health, Inc., an Exact Sciences company, for Oncotype DX Cancer Testing Services. This contract supports the Mike O’Callaghan Military Medical Center at Nellis AFB in Nevada. The contractor will be responsible for providing specimen submission materials, performing genomic tumor-testing, delivering written results and interpretations, and returning tissue tumor blocks or unstained slides. The anticipated period of performance begins on September 16, 2026, and runs through September 15, 2027, with the possibility of four 12-month option periods and one six-month extension. This notice serves as an intent to sole source rather than a request for proposals, though interested sources may submit capability statements by the September 11, 2026, deadline.
General Info
Agency
NAICS
Place of Performance
0, NV, 89191, USASet-Aside
Documents
(1)AI Contract Breakdown
Uniform Contract FormatWhat is UCF?
Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.
Timeline
Response Deadline
Organization & Contact Information
Full Description
The Defense Health Agency Contracting Activity, Healthcare Contracting Division–West, intends to negotiate and award a firm-fixed-price sole-source contract to Genomic Health, Inc., an Exact Sciences company, for Oncotype DX Cancer Testing Services in support of Mike O’Callaghan Military Medical Center, Nellis AFB, Nevada.
The requirement is for the specific Oncotype DX branded genomic tumor-testing service and associated report for eligible patients. The contractor shall provide materials necessary for specimen submission, perform required testing at the contractor’s facility, provide written test results and interpretation, and return tissue tumor blocks or unstained slides in accordance with the resulting contract.
The anticipated period of performance is 16 September 2026 through 15 September 2027, with four 12-month option periods and a potential six-month extension. This is a Notice of Intent to Sole Source and is not a request for competitive quotations or proposals. Interested sources may submit a capability statement by the response deadline stated in this notice.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency Hcd West
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
